|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Planchard D, Popat S, Kerr K, Novello S,
Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil P, Hellmann MD,
et al: Metastatic non-small cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 29 (Suppl 4):iv192–iv237. 2018. View Article : Google Scholar
|
|
3
|
Sawabata N, Miyaoka E, Asamura H,
Nakanishi Y, Eguchi K, Mori M, Nomori H, Fujii Y, Okumura M and
Yokoi K; Japanese Joint Committee for Lung Cancer Registration, :
Japanese lung cancer registry study of 11,663 surgical cases in
2004: Demographic and prognosis changes over decade. J Thorac
Oncol. 6:1229–1235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Akamatsu H, Ninomiya K, Kenmotsu H, Morise
M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, et al:
The Japanese lung cancer society guideline for non-small cell lung
cancer, stage IV. Int J Clin Oncol. 24:731–770. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shields BD, Mahmoud F, Taylor EM, Byrum
SD, Sengupta D, Koss B, Baldini G, Ransom S, Cline K, Mackintosh
SG, et al: Indicators of responsiveness to immune checkpoint
inhibitors. Sci Rep. 7:8072017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kurman JS and Murgu SD: Hyperprogressive
disease in patients with non-small cell lung cancer on
immunotherapy. J Thorac Dis. 10:1124–1128. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fehrenbacher L, Spira A, Ballinger M,
Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D,
Artal-Cortes A, Lewanski C, et al: Atezolizumab versus docetaxel
for patients with previously treated non-small-cell lung cancer
(POPLAR): A multicentre, open-label, phase 2 randomised controlled
trial. Lancet. 387:1837–1846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sade-Feldman M, Jiao YJ, Chen JH, Rooney
MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum
H, Blackmon SM, et al: Resistance to checkpoint blockade therapy
through inactivation of antigen presentation. Nat Commun.
8:11362017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McGranahan N, Rosenthal R, Hiley CT, Rowan
AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Ven Loo P,
Herrero J, et al: Allele-specific HLA loss and immune escape in
lung cancer evolution. Cell. 171:1259–1271.e11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pitt JM, Vetizou M, Daillere R, Roberti
MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M,
Kroemer G and Zitvogel L: Resistance mechanisms to
immune-checkpoint blockade in cancer: Tumor-intrinsic and
-extrinsic factors. Immunity. 44:1255–1269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
O'Donnell JS, Long GV, Scolyer RA, Teng MW
and Smyth MJ: Resistance to PD1/PDL1 checkpoint inhibition. Cancer
Treat Rev. 52:71–81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen L, Gibbons DL, Goswami S, Cortez MA,
Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al: Metastasis
is regulated via microRNA-200/ZEB1 axis control of tumour cell
PD-L1 expression and intratumoral immunosuppression. Nat Commun.
5:52412014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Loi S, Dushyanthen S, Beavis PA, Salgado
R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV,
et al: RAS/MAPK Activation is associated with reduced
tumor-infiltrating lymphocytes in triple-negative breast cancer:
Therapeutic cooperation between MEK and PD-1/PD-L1 immune
checkpoint inhibitors. Clin Cancer Res. 22:1499–1509. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Soundararajan R, Fradette JJ, Konen JM,
Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy
D, Bernatchez C, et al: Targeting the interplay between
epithelial-to-mesenchymal-transition and the immune system for
effective immunotherapy. Cancers (Basel). 11:7142019. View Article : Google Scholar
|
|
21
|
Su MW, Dorocicz I, Dragowska WH, Ho V, Li
G, Voss N, Gascoyne R and Zhou Y: Aberrant expression of T-plastin
in sezary cells. Cancer Res. 63:7122–7127. 2003.PubMed/NCBI
|
|
22
|
Giganti A, Plastino J, Janji B, Van Troys
M, Lentz D, Ampe C, Sykes C and Friederichet E: Actin-filament
cross-linking protein T-plastin increases Arp2/3-mediated
actin-based movement. J Cell Sci. 118:1255–1265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yokobori T, Iinuma H, Shimamura T, Imoto
S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, et
al: Plastin3 is a novel marker for circulating tumor cells
undergoing the epithelial-mesenchymal transition and is associated
with colorectal cancer prognosis. Cancer Res. 73:2059–2069. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kaira K, Higuchi T, Naruse I, Arisaka Y,
Tokue A, Altan B, Suda S, Mogi A, Shimizu K, Sunaga N, et al:
Metabolic activity by 18F-FDG-PET/CT is predictive of
early response after nivolumab in previously treated NSCLC. Eur J
Nucl Med Mol Imaging. 45:56–66. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumors:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kurashige J, Yokobori T, Mima K, Sawada G,
Takahashi Y, Ueo H, Takano Y, Matsumura T, Uchi R, Eguchi H, et al:
Plastin3 is associated with epithelial-mesenchymal transition and
poor prognosis in gastric cancer. Oncol Lett. 17:2393–2399.
2019.PubMed/NCBI
|
|
27
|
Vargas AJ and Harris CC: Biomarker
development in the precision medicine era: Lung cancer as a case
study. Nat Rev Cancer. 16:525–537. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grunnet M and Sorensen JB:
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung
Cancer. 76:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
De Stefano F, Chacon E, Turcios L, Marti F
and Gedaly R: Novel biomarkers in hepatocellular carcinoma. Dig
Liver Dis. 50:1115–1123. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shimada H, Noie T, Ohashi M, Oba K and
Takahashi Y: Clinical significance of serum tumor markers for
gastric cancer: A systematic review of literature by the task force
of the Japanese gastric cancer association. Gastric Cancer.
17:26–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shrestha R, Prithviraj P, Anaka M, Bridle
KR, Crawford DHG, Dhungel B, Steel JC and Jayachandran A:
Monitoring immune checkpoint regulators as predictive biomarkers in
hepatocellular carcinoma. Front Oncol. 8:2692018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dodagatta-Marri E, Meyer DS, Reeves MQ,
Paniagua R, To MD, Binnewies M, Broz ML, Mori H, Wu D, Adoumie M,
et al: α-PD-1 therapy elevates Treg/Th balance and increases tumor
cell pSmad3 that are both targeted by α-TGFβ antibody to promote
durable rejection and immunity in squamous cell carcinomas. J
Immunother Cancer. 7:622019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sugimachi K, Yokobori T, Iinuma H, Ueda M,
Ueo H, Shinden Y, Eguchi H, Sudo T, Suzuki A, Maehara Y, et al:
Aberrant expression of plastin-3 via copy number gain induces the
epithelial-mesenchymal transition in circulating colorectal cancer
cells. Ann Surg Oncol. 21:3680–3690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ueo H, Sugimachi K, Gorges TM, Bartkowiak
K, Yokobori T, Müller V, Shinden Y, Ueda M, Ueo H, Mori M, et al:
Circulating tumour cell-derived plastin3 is a novel marker for
predicting long-term prognosis in patients with breast cancer. Br J
Cancer. 112:1519–1526. 2015. View Article : Google Scholar : PubMed/NCBI
|
